EUVIMEDEUVIMED entdecken
Open Access

18 F-FAPI-04 Outperforms 18 F-FDG PET/CT in Clinical Assessments of Patients with Pancreatic Adenocarcinoma

Xiang Li, Na Lu, Lili Lin, Yiwen Chen, Shuye Yang, Huatao Wang, Xinyuan Liu, Chengyi Wu, Xing Xue, Xinhui Su, Xueli Bai, Tingbo Liang

Journal of Nuclear Medicine · 2024-02 · 65 (2) · 206-212

DOI: 10.2967/jnumed.123.266283 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 04.01.2024. Verfasst von Xiang Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Adenocarcinoma, Carcinoma, Pancreatic Ductal, Quinolines. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Accurate diagnosis and staging are crucial for selecting treatment for patients with pancreatic ductal adenocarcinoma (PDAC). The desmoplastic responses associated with PDAC are often characterized by hypometabolism. Here, we investigated 18F-fibroblast activation protein inhibitor (FAPI)-04 PET/CT in evaluation of PDAC and compared the findings with those obtained using 18F-FDG.

Methods

Sixty-two PDAC patients underwent 18F-FAPI-04 PET/CT and 18F-FDG PET/CT. Identification of primary lesions, lymph node (LN) metastasis, and distant metastasis (DM) by these methods was evaluated, and TNM staging was performed. Correlation between SUVmax of the primary lesion and treatment response was explored in patients who received systemic therapy.

Results

18F-FAPI-04 PET/CT identified all patients with PDAC; 18F-FDG PET/CT missed 1 patient. Tracer uptake was higher in 18F-FAPI-04 PET/CT than in 18F-FDG PET/CT in primary tumors (10.63 vs. 2.87, P < 0.0001), LN metastasis (2.90 vs. 1.43, P < 0.0001), and DM (liver, 6.11 vs. 3.10, P = 0.002; peritoneal, 4.70 vs. 2.08, P = 0.015). The methods showed no significant difference in the T staging category, but the N and M values were significantly higher for 18F-FAPI-04 PET/CT than for 18F-FDG PET/CT (P = 0.002 and 0.008, respectively). Thus, 14 patients were upgraded, and only 1 patient was downgraded, by 18F-FAPI-04 PET/CT compared with 18F-FDG PET/CT. A high SUVmax of the primary tumor did not correlate with treatment response for either 18F-FAPI-04 or 18F-FDG.

Conclusion

18F-FAPI-04 PET/CT performed better than 18F-FDG PET/CT in identification of primary tumors, LN metastasis, and DM and in TNM staging of PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsAdenocarcinomaCarcinoma, Pancreatic DuctalQuinolinesHumansPositron Emission Tomography Computed TomographyFluorodeoxyglucose F18Lymphatic MetastasisGallium Radioisotopes

Stichwörter der Autor:innen

18F-FAPI-0418F-FDGPET/CTpancreatic ductal adenocarcinomastaging

Substanzen

Fluorodeoxyglucose F1868Ga-FAPIGallium RadioisotopesQuinolines

Autor:innen und Institutionen

  • Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
  • Zhejiang Provincial Key Laboratory of Pancreatic Disease, Hangzhou, China.
  • Department of Nuclear Medicine, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
  • Department of Radiology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China; and.
  • Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China; liangtingbo@zju.edu.cn shirleybai@zju.edu.cn.
  • Zhejiang University Cancer Center, Hangzhou, China.

Zitieren

APA

Li, X., Lu, N., Lin, L., Chen, Y., Yang, S., Wang, H., Liu, X., Wu, C., Xue, X., Su, X., Bai, X., & Liang, T. (2024). 18 F-FAPI-04 Outperforms 18 F-FDG PET/CT in Clinical Assessments of Patients with Pancreatic Adenocarcinoma. Journal of Nuclear Medicine, 65(2), 206-212. https://doi.org/10.2967/jnumed.123.266283

Vancouver

Li X, Lu N, Lin L, Chen Y, Yang S, Wang H, et al. 18 F-FAPI-04 Outperforms 18 F-FDG PET/CT in Clinical Assessments of Patients with Pancreatic Adenocarcinoma. Journal of Nuclear Medicine. 2024;65(2):206-212. doi:10.2967/jnumed.123.266283

BibTeX
@article{Li2024,
  author = {Li, Xiang and Lu, Na and Lin, Lili and Chen, Yiwen and Yang, Shuye and Wang, Huatao and Liu, Xinyuan and Wu, Chengyi and Xue, Xing and Su, Xinhui and Bai, Xueli and Liang, Tingbo},
  title = {18 F-FAPI-04 Outperforms 18 F-FDG PET/CT in Clinical Assessments of Patients with Pancreatic Adenocarcinoma},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  volume = {65},
  number = {2},
  pages = {206--212},
  doi = {10.2967/jnumed.123.266283}
}
Kostenlos starten →